
News &
Media
-
Neurotech embarks on ground-breaking ASD trials
Neurotech International Limited (ASX:NTI) has commenced a Phase I/II open label clinical study in 20 children aged between 5-17 years with Autism Spectrum Disorder (ASD).
-
Neurotech International (ASX:NTI) secures option to Dolce Cann Global’s cannabis strains
Neurotech International (NTI) has secured an option to acquire an exclusive worldwide licence to use cannabis strains from Dolce Cann Global.
The proprietary cannabis strains will be medicinally used to treat neurological disorders such as autism, epilepsy and ADHD.